Stryker report:
Investment Dossier · Healthcare / Medical Technology
Quality Watch · Start SmallStryker: A Rare Quality Compounder at a More Ordinary Multiple
The sell-off has not made Stryker statistically cheap. It has made an exceptional medical-technology franchise investable at roughly 21.7× 2026 adjusted earnings. Our preference is a smaller opening position, with capital reserved for further weakness.
Muffett Investments · 2 August 2026 · NYSE: SYK · Price at analysis: US$325.70 (31 July close) · Research, not investment advice
Stryker closed 31 July at US$325.70, down 6.4% on the day and roughly 20% below its 52-week high. Against management's narrowed 2026 adjusted EPS guidance of US$14.95–15.10, the shares trade at 21.7 times the midpoint. That is not the 20 times sometimes quoted, but it is close—and materially less demanding than the premium usually attached to Stryker's consistent high-single-digit organic growth.
The latest operating evidence remains strong: Q2 sales rose 9.4% to US$6.6 billion, organic growth was 9.0%, adjusted operating margin reached 27.4%, and adjusted EPS increased 17.9%. The immediate caution is that the company is recovering from a cyber incident, and the valuation still assumes sustained execution.
Why we are interested
Quality repriced
A broad portfolio, entrenched surgeon relationships and strong procedural demand now come at a lower—but not distressed—multiple.
What the market fears
Growth deceleration
A premium compounder can de-rate sharply if procedure volumes, capital-equipment demand or margin expansion disappoint.
What changes the outcome
Asia and execution
International penetration, Mako adoption, trauma growth and clean recovery from the cyber disruption.
Our Position
Begin with a smaller position; add only into weakness. The valuation has improved enough to start building exposure, but not enough to remove downside risk. We would preserve at least half of the intended allocation for a lower price or fresh evidence that execution remains intact.
02 · Business and Strategic Advantage
Stryker Is Broader Than an Arthroplasty Thesis
Stryker's 2025 sales were US$25.1 billion. MedSurg and Neurotechnology contributed US$15.6 billion, while Orthopaedics contributed US$9.5 billion. Within Orthopaedics, Trauma and Extremities was the largest category at US$3.95 billion—larger than Knees at US$2.66 billion or Hips at US$1.87 billion.
| Platform | 2025 sales | Strategic role |
|---|---|---|
| MedSurg & Neurotechnology | US$15.65B | Instruments, endoscopy, emergency care, neurovascular and neuro-cranial products diversify the earnings engine. |
| Trauma & Extremities | US$3.95B | Broad fracture fixation exposure, including the rising burden of fragility and periprosthetic fractures. |
| Knees & Hips | US$4.52B | Implants reinforced by Mako robotics, planning software, installed systems and surgeon workflow. |
| Asia Pacific | US$2.16B | Only 8.6% of group sales today, leaving meaningful—but execution-dependent—white space. |
Stryker versus Zimmer: our preference, with one correction
Stryker's absolute year-end 2025 debt was higher—US$15.9 billion versus Zimmer's US$7.5 billion—following acquisitions. Relative leverage tells a different story. Debt equalled roughly 63% of Stryker's annual sales versus 91% for Zimmer; Zimmer's net debt was also about 4.1 times annual operating cash flow, compared with roughly 2.4 times for Stryker using year-end cash and 2025 cash generation. These are simple comparison lenses, not covenant ratios, but they support the view that Stryker has greater balance-sheet capacity.
Why we prefer Stryker
Faster organic growth, broader end markets, a larger trauma franchise, Mako's ecosystem and stronger cash-generation coverage of debt.
Why Zimmer can still win
A more concentrated hip-and-knee franchise could outperform if arthroplasty volumes surge, execution improves and its lower valuation re-rates.
03 · What the Market May Be Missing
Asia Is Small Today—and Potentially Material Tomorrow
1. Demography creates duration, not automatic revenue
Population ageing is a genuine long-run tailwind: the UN expects the global 65-plus share to rise from one in eleven people in 2019 to one in six by 2050, with especially rapid ageing in Eastern and South-Eastern Asia. China combines a very large older population with rising treatment capacity; India combines a vast population, increasing longevity and expanding private healthcare. Yet demographics alone do not guarantee Stryker sales—reimbursement, surgeon training, hospital capital budgets and local pricing determine conversion.
2. The current exposure is smaller than the opportunity
Asia-Pacific produced US$2.164 billion of 2025 revenue, 8.6% of the group—consistent with describing the region as “about 10%” while showing why Asia cannot drive near-term earnings by itself. Stryker has operated commercially in India since 1999, now employs more than 1,000 people there, maintains multiple strategic sites in China and runs an APAC medical-education centre in Hong Kong. The infrastructure exists; the investment question is whether growth outpaces the group for many years.
3. Trauma broadens the ageing thesis
Ageing does not only increase primary hip and knee replacement. Osteoporosis and longer implant survival also increase fracture complexity and the population living with existing implants. Stryker's US$3.95 billion Trauma and Extremities franchise therefore gives it exposure to fragility and periprosthetic fracture care that a narrow arthroplasty thesis can miss.
Today
8.6% APAC
Material enough to prove presence; too small to dominate current earnings.
Near term
8.3–9.3%
Management's 2026 organic sales-growth range remains the key execution benchmark.
Long term
Platform pull-through
Mako placements, implants, instruments, service and training can reinforce one another.
04 · Valuation and Investment Decision
Good Entry Point; Not Yet a Full-Position Price
The following three-year scenarios are Muffett valuation tools, not company guidance or conventional twelve-month targets. They apply illustrative 2028 adjusted EPS and exit multiples to show what must happen for the current price to work.
| Scenario | 2028 adj. EPS | Exit P/E | Illustrative value | Price return | What must be true |
|---|---|---|---|---|---|
| Bear | US$15.50 | 18× | US$279 | −14% | Growth falls to mid-single digits, cyber recovery lingers and multiple compression continues. |
| Base | US$18.50 | 23× | US$426 | +31% | High-single-digit organic growth persists, margins hold and APAC gradually outgrows the group. |
| Bull | US$21.00 | 27× | US$567 | +74% | Mako and broad portfolio share gains compound, Asia accelerates and premium execution returns. |
| Thesis confirmation | Thesis breaker |
|---|---|
| Organic sales remain near the high-single digits through normal procedure volatility. | Sustained growth below 6% without a clear temporary cause. |
| APAC grows faster than the group and rises steadily above its 8.6% mix. | China pricing, localisation or capital constraints keep APAC structurally subscale. |
| Trauma and Extremities continues to outgrow mature hip and knee categories. | Share loss or product issues undermine the broader-platform advantage. |
| Debt declines relative to cash generation after the acquisition cycle. | Further large acquisitions prevent balance-sheet repair. |
| Adjusted operating margin holds near the high-20s. | Persistent cyber, tariff, pricing or mix pressure erodes margins. |
Final Muffett View
Preferred to Zimmer, but sized with humility. Stryker offers the stronger combination of growth, breadth, trauma exposure and leverage coverage. At 21.7× guided 2026 earnings, we would open a smaller position—roughly one-third to one-half of the intended allocation—and add only if price weakness creates a wider margin of safety or operating evidence strengthens. Quality reduces business risk; it does not eliminate valuation risk.
Principal sources
- Stryker Q2 2026 results — sales, organic growth, margins, EPS and guidance.
- Stryker 2025 Form 10-K, recast presentation — geographic, segment, product, cash-flow and debt data.
- Zimmer Biomet 2025 annual report — product mix, sales, debt and cash flow.
- United Nations: Ageing — global demographic outlook.
- Stryker locations — India, China and regional infrastructure.
Market price and market capitalisation are as of 31 July 2026. Adjusted measures are non-GAAP and should be read with company reconciliations. Comparative leverage ratios and scenario values are Muffett calculations; scenario outputs are illustrative and exclude dividends.
This independent research is provided for informational and educational purposes only and does not constitute personal investment advice or a recommendation to transact. Medical-technology equities face regulatory, litigation, reimbursement, competitive, cybersecurity and valuation risks. Capital is at risk.
